Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683416 | 0.84 | NFE2L2 (0.39) | CYP1A2SIGMAR1EPHX1HPGDNFE2L2 | |
| SCHEMBL18183827 | 0.80 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL15227499 | 0.78 | NFE2L2 (0.31) | NFE2L2 | |
| SCHEMBL3025958 | 0.78 | CYP1A2 (0.41) | CYP1A2SIGMAR1EPHX1HRH3SMN1; SMN2 | |
| SCHEMBL5543638 | 0.77 | CYP1A2 (0.45) | CYP1A2SIGMAR1EPHX1HRH3SMN1; SMN2 | |
| SCHEMBL3258085 | 0.77 | CYP1A2 (0.45) | CYP1A2SIGMAR1EPHX1HRH3SMN1; SMN2 | |
| SCHEMBL5541873 | 0.77 | CYP1A2 (0.45) | CYP1A2SIGMAR1EPHX1HRH3SMN1; SMN2 | |
| SCHEMBL7048958 | 0.77 | — | — | |
| SCHEMBL13619710 | 0.77 | — | — | |
| SCHEMBL14739553 | 0.76 | CYP1A2 (0.52) | CYP1A2SIGMAR1EPHX1HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | CYP1A2 198/4885SIGMAR1 2324/4885EPHX1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.